

# NextGen

## Homologous Recombination Deficiency

### Patient Selection



Patients with  
Ovarian cancer

### Technology



Next Generation  
Sequencing &  
Multiplex Ligation  
Dependent Probe  
Amplification

### Specimen



FFPE Block &  
Whole Blood

### Test Code



N8275

### TAT



4 weeks




Detection and classification of sequence variants (SNVs & Indels) in 28 HRR pathway genes & BRCA1/2 Deletion-Duplication analysis by MLPA



Comprehensive assessment of Loss of heterozygosity (LOH) , Telomeric allelic imbalance (TAI) and Large-scale transition (LST) across the entire genome to evaluate genomic instability



Determines the eligibility for PARP Inhibitors



Provides Genomic Scar Score

### HRR pathway genes covered in Panel:

ATM	BARD1	BRCA1	BRCA2	BRIP1	CDK12	CHEK2
FANCD2	MRE11	NBN	PALB2	PPP2R2A	RAD51B	RAD54L
TP53	CHEK1	FANCL	RAD50	RAD51	RAD51C	RAD51D
RAD52	XRCC2	KRAS	PIK3CA	POLD1	POLE	PTEN



# NextGen

## Homologous Recombination Deficiency

### Your Test Results

METROPOLIS

Case Number:

Patient Name:

Age/Sex:

Patient Location:

Hospital Name:

Physician Name:

Date & Time of Accessioning:

Date & Time of Reporting:

#### Test Performed

Homologous Recombination Deficiency

#### Specimen Information

Received 7 paraffin blocks

#### Clinical Indication

K/C/O ca ovary

#### Results

Genomic Instability (LOH+NtAI+ST)	Positive (HRD Score:61)
HRR Pathway gene Mutations: (Germline+Somatic Study)	Positive
BRCA1 & BRCA2 Deletion Duplication study by MLPA (Somatic+germine Study)	Negative

#### Interpretation:

- GenomeSignature panel analysis of the provided FFPE tissue block (A0091648A-G) revealed HRD score of homologous re-combination deficient signature. HRD score 61 was calculated based on three biomarkers (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions).
- Somatic HRR gene panel analysis revealed pathogenic variant in TP53 gene. (Details attached).

\*Homologous Recombination Deficiency is calculated by proprietary algorithm developed at CORE Diagnostics based on three biomarkers (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions)



Genomic Scar Score:  $\geq 50$

HRD Status: Positive

Corporate Office: Metropolis Healthcare Limited, 4th Floor, East Wing, Plot-254 B, Nirlon House,  
Dr, Annie Besant Road, Worli Mumbai - 400030, Maharashtra, India

[www.metropolisindia.com](http://www.metropolisindia.com)